Research-Grade Peptides.
Lab-Tested. Shipped Fast.
Axio Peptides supplies high-purity research compounds to laboratories and independent researchers. Verified by third-party analysis, dispatched the same day.
Best Sellers
Most requested research compounds this season.
BPC-157
Synthetic pentadecapeptide studied in tissue research.
GHK-Cu
Copper tripeptide-1 used in dermal and matrix research.
TB-500
Synthetic fragment of thymosin beta-4.
GHK-Cu / BPC-157 / TB-500 Blend
Tri-peptide research blend.
Semaglutide
GLP-1 receptor agonist analogue for in-vitro study.
Tirzepatide
Dual GIP/GLP-1 receptor agonist analogue.
Why researchers choose Axio
We exist to make verified, research-grade peptides accessible — without the markup or the wait. Every batch is independently analyzed and shipped under conditions designed to preserve integrity.
- ≥ 99% purity by HPLCReverse-phase HPLC and mass-spec verification on every lot.
- Cold-chain dispatchTemperature-controlled shipping protects lyophilized integrity.
- Certificates on demandLot-matched COAs available for every order.
Shop All Peptides
Explore our full catalog of third-party tested research compounds.
BPC-157
Synthetic pentadecapeptide studied in tissue research.
GHK-Cu
Copper tripeptide-1 used in dermal and matrix research.
TB-500
Synthetic fragment of thymosin beta-4.
GHK-Cu / BPC-157 / TB-500 Blend
Tri-peptide research blend.
Contact Us
Questions about a product, an order, or a lot certificate? Send us a message and our team will get back to you within one business day.
Email: support@pxptide.com
Hours: Mon–Fri, 9am–5pm ET
The statements on this website have not been evaluated by the U.S. Food and Drug Administration. The products and information provided by Lumin Peptides are not intended to diagnose, treat, cure, or prevent any disease. Axio Peptides LLC is a research chemical supplier. We are not a compounding pharmacy or compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor are we an outsourcing facility as defined under Section 503B.